TC
ADPT icon

Truvestments Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Truvestments Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-229
Closed -$1.75K – 674
2022
Q4 		$1.75K Buy
+229
New +$1.78K ﹤0.01% 749

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Truvestments Capital's ADPT Position: Q1 2023 in Review

Truvestments Capital sold out of Adaptive Biotechnologies (ADPT) in Q1 2023, closing a stake of 229 shares — an estimated $1.75K sold.

Truvestments Capital first reported a position in ADPT in Q4 2022 and held it in 1 quarter. The position peaked at $1.75K in Q4 2022. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

  • Truvestments Capital reported no remaining Adaptive Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Truvestments Capital sold 229 Adaptive Biotechnologies shares in Q1 2023, an estimated $1.75K.
  • Truvestments Capital first reported a position in Adaptive Biotechnologies in Q4 2022 and held it in 1 quarter.
  • Truvestments Capital's Adaptive Biotechnologies position peaked at $1.75K in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Truvestments Capital's 13F filing for Q1 2023, filed 12 May 2023.